Biotronik, a manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, and Endosense have entered into an exclusive distribution agreement for Endosense's force-sensing ablation catheter, the TactiCath.

Under the terms of the agreement, Biotronik is expected to be the distributor of the TactiCath in all major markets outside of the US, Japan and Asia.

The device has been granted CE mark for atrial fibrillation (AF) and supraventricular tachycardia (SVT) indications in 2009, the TactiCath is the force-sensing ablation catheter to give physicians objective measure of contact force during cardiac ablation procedures.

Marlou Janssen, global vice president of marketing and CRM of sales at Biotronik, said: “The extensive clinical study and initial clinical use of the TactiCath have proven its potential to significantly improve the efficacy, safety and reproducibility of catheter ablation procedures, an achievement that is consistent with our commitment to drive positive change in clinical practice.

“The technology and the Swiss engineering quality match well with our corporate strategy for quality and innovation. We look forward to joining forces to bring this great innovation to market.”

Eric Le Royer, president and chief executive officer of Endosense, said: “We expect the new partnership between Endosense and Biotronik to boost the commercial adoption of the TactiCath. Biotronik has all the attributes to contribute to this success with shared values, a proven track record and a very established presence in the market.

“Our partnership will produce a major step forward in the area of cardiac ablation, as we will address the unmet need of absolute force control in the electrophysiology lab and, by doing so, change clinical practice.”